Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment …

Biotechnology

US, Houston [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about Moleculin Biotech, Inc.'s gradings, price targets and earnings estimates. None

Earnings
Grading & Price

Reported

Past Estimate Consensus

Future Estimate Consensus

Moleculin Biotech, Inc. can't present any analysts estimates at the moment detail analysis.